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Summary
Objectives: To retrospectively determine the prevalence of anti-hepatitis A virus (HAV) antibody
in HIV-positive persons with different routes of HIV exposure and to describe its characteristics in
order to guide vaccination policy.
Methods: The prevalence of anti-HAVantibody was compared between 1580 HIV-positive persons
seeking medical attention and 2581 HIV-negative controls seeking health check-ups, who had
undergone anti-HAV tests between 2004 and 2007. Comparisons were also made among groups of
the HIV-positive patients who had acquired HIV via different routes of transmission. A multi-
variate logistic regression model was built to identify independent variables associated with anti-
HAV seropositivity.
Results: The overall prevalence of anti-HAV antibody was 60.9% in the HIV-positive and 48.0% in
the controls (p < 0.001). The overall adjusted odds ratio (AOR) for positive anti-HAVantibody was
2.604 (95% confidence interval (CI) 2.106—3.219) in HIV-positive persons compared with HIV-
negative persons. In addition, HIV-positive men who have sex with men (MSM), heterosexuals, and
injecting drug users (IDU) all had significantly higher AOR for positive anti-HAVantibody than HIV-
negative persons. In HIV-positive persons, older age (AOR 1.284, 95% CI 1.246—1.322) and IDU
(AOR 5.137, 95% CI 3.499—7.542) were independently associated with an increased prevalence of
anti-HAVantibody. Nearly 90% of the IDU had become seropositive for HAVafter age 36—40 years,
compared with heterosexuals and MSM after age 46—50 years, and controls after age 51—55 years.
* Corresponding author. Tel.: +886 2 23123456x67552; fax: +886 2 23707772.
E-mail address: hcc0401@ntu.edu.tw (C.-C. Hung).
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Conclusion: Our findings suggest that age groups to be targeted for HAV vaccination vary with the
different routes of HIV exposure.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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By the end of 2007, 15 011 cases of HIV infection had been
reported in Taiwan since 1984.1 With a population of 23
million, the HIV prevalence rate among adults aged 15—49
years in Taiwan was estimated to be 0.07% in 2007.1 Before
2003, men who have sex with men (MSM) accounted for the
largest proportion of the HIV-infected population (53.3%),
followed by heterosexuals (41.9%).1 However, since 2003, HIV
has been widely spread among injecting drug users (IDU)
through the sharing of needles and heroin diluents; the
number of cases of HIV infection acquired through injecting
drug use increased rapidly between 2003 and 2006, and IDU
accounted for more than two thirds of all cases of newly
diagnosed HIV infection in 2005 and 2006.2 Fortunately, the
spread of HIV has been curbed with the rapid implementation
and expansion of a harm-reduction program around the
island.2
Persons at risk for HIV infection are at high risk for
hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
because of the shared transmission routes of these viruses.3
Although hepatitis A virus (HAV) is mainly transmitted
through the fecal—oral route,4,5 numerous outbreaks of
HAV infection have been reported in the IDU and MSM popula-
tions.6—14 A higher prevalence of anti-HAV antibody has been
observed in IDU than in the general population,15—17 while a
higher prevalence of anti-HAV antibody has not been consis-
tently observed in MSM compared with the general popula-
tion.15,18,19 Since patients with chronic HBV or HCV infection
are at higher risk for fulminant hepatic failure, increased
morbidity, and a high case-fatality rate after acute HAV
infection,6,20,21 HAV vaccination is recommended for MSM,
IDU, and persons with chronic liver disease.22,23
In Taiwan, the overall prevalence of anti-HAV antibody in
the general population has declined from 25.6% to 15.5%
after improvements in socioeconomic status and sanita-
tion.24,25 However, the prevalence of anti-HAV antibody
among HIV-positive persons after the HIV outbreak in IDU
in Taiwan since 2003 remains unknown. Thus, the present
study aimed to determine the prevalence of anti-HAV anti-
body among HIV-positive IDU, MSM, and heterosexuals and to
describe its characteristics by comparisons with those of HIV-
negative persons. Analysis of the prevalence within specific
age groups was made among persons with different routes of
HIV exposure in order to guide vaccination policy.
Materials and methods
Non-hemophilic HIV-positive persons aged 15 years or older,
who sought medical care for HIV infection and who were
tested for anti-HAV antibody between 2004 and 2007 at the
National Taiwan University Hospital, Taipei and Yun-Lin
Branch, were enrolled in the present study. HIV infection
was diagnosed by detection of anti-HIV antibody using ELISA
or particle agglutination and confirmed by Western blot test.
The control group consisted of consecutive HIV-negativepersons aged 15 years or older who sought a health check-
up, but not due to infection or disease, at the same hospitals
during the same study years. Unlike the HBV control program
in which HBV vaccination was implemented nationwide in
Taiwan from 1984, HAV vaccination is not mandatory and is
mainly recommended to persons who plan to travel abroad to
regions of higher HAV endemicity.
A computerized data collection form was used to retro-
spectively retrieve demographic and clinical data, which
included birth date, sex, HIV transmission route, baseline
CD4+ lymphocyte count and plasma HIV RNA load, and test
results of baseline anti-HAV antibody, anti-HCV antibody,
hepatitis B surface antigen (HBsAg), and anti-hepatitis B core
antibody (anti-HBc antibody). The institutional review
boards of the hospitals approved the study and waived the
need for informed consent.Anti-HAV antibody was deter-
mined with the use of Hepavase A96 TMB (General Biologicals
Corp., Hsin-Chu, Taiwan) with sensitivity of 99.8% and spe-
cificity of 99.5%. HBsAg and anti-HBc antibody were deter-
mined with the use of enzyme immunoassays (Abbott
Laboratories, IL, USA). Antibodies to HCV were determined
with the use of a third-generation enzyme immunoassay (Ax
SYM HCV III, Abbott Laboratories, IL, USA). Anti-HIV antibody
was tested using particle agglutination (SFD HIV 1/2 PA, Bio-
Rad FUJIREBIO, Japan) and confirmed using Western blot (MP
Diagnostics HIV BLOT 2.2. MP Biomedicals Asia Pacific Pte Ltd,
Singapore). Plasma HIV RNA loads were quantified using
reverse transcriptase-polymerase chain reaction (RT-PCR;
Roche Amplicor, version 1.5, NJ, USA) with a lower detection
limit of 400 (2.60 log10) copies/ml. CD4 counts were deter-
mined using FACFlow (BD FACS Calibur, Becton Dickinson, CA,
USA).
All statistical analyses were performed using SPSS soft-
ware version 15.0 (SPSS Inc., Chicago, IL, USA). Categorical
variables were compared using the Chi-square or Fisher’s
exact test, whereas non-categorical variables were com-
pared using the Mann—Whitney U-test. A multiple logistic
regression model was built to identify independent variables
associated with anti-HAV seropositivity. All tests were two-
tailed and a p-value of <0.05 was considered significant.
Results
During the study period, a total of 2374 HIV-positive patients
sought HIV care and 2581 HIV-negative persons sought a
health check-up. While all HIV-negative persons were tested
for anti-HAV antibody, two-thirds of the HIV-positive persons
(n = 1580; 66.6%) were tested for anti-HAV antibody. Among
the HIV-positive patients, IDU had the highest anti-HAV test-
ing rate (72.9%), followed by heterosexuals (69.6%) and MSM
(61.7%). Compared with the HIV-positive patients who did not
undergo anti-HAVantibody tests, those patients who received
such tests were more likely to be older and IDU, and had
lower plasma HIV RNA (data not shown).
Compared with HIV-negative persons, a higher proportion
of HIV-positive persons who had anti-HAV tests were men
Table 1 Demographics of HIV-negative and HIV-positive persons with different routes of HIV transmission
Total HIV-positive
persons
Men who have
sex with men
Heterosexuals Injecting drug
users
HIV-negative
persons
Number of cases 1580 658 (41.6) 304 (19.2) 577 (36.5) 2581
Men, n (%) 1469 (93.0) c 658 (100) c 232 (76.3) c 542 (93.9) c 1790 (69.4)
Median agea (range), years 39 (19—89) c 40 (22—89) c 48 (23—86)c 34 (21—61) c 38 (17—95)
Age, years
<26, n (%) 52 (3.3) 13 (2.0) 1 (0.3) 34 (5.9) 937 (36.3)
26—30 219 (13.9) 74 (11.2) 6 (2.0) 138 (23.9) 150 (5.8)
31—35 289 (18.3) 119 (18.1) 18 (5.9) 148 (25.6) 139 (5.4)
36—40 311 (19.7) 158 (24.0) 47 (15.5) 104 (18.0) 113 (4.4)
41—45 285 (18.0) 138 (21.0) 58 (19.1) 78 (13.5) 147 (5.7)
46—50 171 (10.8) 76 (11.6) 47 (15.5) 45 (7.8) 185 (7.2)
51—55 94 (5.9) 40 (6.1) 30 (9.9) 20 (3.5) 192 (7.4)
>55 159 (10.1) 40 (6.1) 97 (31.9) 10 (1.7) 718 (27.8)
Median CD4a (range), cells/ml 245 (0—1943) 118 (0—1202) 50 (0—938) 387 (1—1943) NA
Median CD8 (range), cells/ml 828 (6—4417) 667 (27—4417) 546 (6—3457) 1058 (115—4379) NA
Median plasma HIV RNA (range),
log10 copies/ml
4.5 (1.7—6.3) 5.2 (1.7—6.0) 5.2 (1.7—5.9) 4.1 (2.6—6.0) NA
Positive anti-HAV antibody, n (%) 962 (60.9) c 332 (50.5) 241 (79.3) c 358 (62.0) c 1239 (48.0)
Positive HBsAg, n/Nb (%) 308/1546 (19.9) c 135/657 (20.5) c 57/303 (18.8) c 109/548 (19.9) c 340 (13.2)
Positive anti-HBc antibody, n/Nb (%) 1170/1449 (80.7) c 481/597 (80.6) c 229/286 (80.1) c 434/532 (81.6) c 1482 (57.4)
Positive anti-HCV antibody, n/Nb (%) 595/1444 (41.2) c 38/590 (6.4)c 21/282 (7.4) c 529/538 (98.3) c 19/1064 (1.8)
anti-HAV, anti-hepatitis A virus; HBsAg, hepatitis B surface antigen; anti-HBc, anti-hepatitis B core; anti-HCV, anti-hepatitis C virus.
a p < 0.001 for comparisons among men having sex with men (MSM), heterosexuals, and injecting drug users (IDU), between MSM and
heterosexuals, between MSM and IDU, and between heterosexuals and IDU.
b n/N = number of patients with positive test result/number of patients with test result.
c Compared with HIV-negative persons, p < 0.05.
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HIV-negative persons were aged less than 26 years and 27.8%
were aged over 55 years. However, 86.6% of the HIV-positive
persons were aged between 26 and 55 years; only 3.3% and
10.1% were aged less than 26 and over 55 years, respectively.
Except for 41 (2.6%) HIV-positive persons who had unknown
routes of HIV transmission, 658 (41.6%) HIV-positive persons
were MSM, 304 (19.2%) were heterosexuals, and 577 (36.5%)
were IDU (Table 1). HIV-positive heterosexuals were older
than HIV-negative persons and HIV-positive MSM and IDU
(Table 1, all comparisons, p < 0.001). Of HIV-positive per-
sons, heterosexuals were much more immunocompromised
at enrollment than MSM or IDU in terms of CD4 count (Table 1,
all comparisons, p < 0.001). MSM and heterosexuals had
similar HIV RNA load, and both MSM and heterosexuals had
higher HIV RNA loads than IDU.
The overall prevalence of anti-HAV antibody was 60.9% in
HIV-positive persons and 48.0% in HIV-negative persons
( p < 0.001; Table 1). After adjustment for sex and age,
the adjusted odds ratio (AOR) for positive anti-HAV antibody
was 2.604 (95% confidence interval (CI) 2.106—3.219) in HIV-
positive persons compared with HIV-negative persons. The
risk for positive anti-HAV antibody varied with different
routes of HIV exposure; compared with controls after adjust-
ment for age and sex, AOR for positive anti-HAVantibody was
1.403 (95% CI 1.073—1.834) in MSM, 1.887 (95% CI 1.306—
2.726) in heterosexuals, and 6.551 (95% CI 4.930—8.705) in
IDU.
Among HIV-positive persons, a higher proportion of het-
erosexuals (79.3%) had positive anti-HAV antibody than IDU(62.0%, p < 0.001) and MSM (50.5%, p < 0.001), which might
be due to the fact that heterosexuals were older than the
other HIV-positive groups (Table 1). If HIV-positive persons
were categorized according to age-specific groups, the pre-
valence of anti-HAV antibody was significantly higher in HIV-
positive IDU (23.9—95.6%) than in MSM (10.8—76.3%) or HIV-
negative persons (14.0—77.8%) aged from 26 to 50 (all com-
parisons, p < 0.05; Figure 1). Compared with heterosexuals
(27.8—77.6%), IDU aged 31—45 years had a much higher
prevalence of anti-HAV antibody (58.8—92.3%; all compar-
isons, p < 0.05).
To evaluate the relationship between immune status and
prevalence of anti-HAV antibody, we grouped HIV-infected
persons into three CD4+ count categories: <200, 200—350,
and>350 cells/ml (Table 2).We found that the lower the CD4
count, the higher the prevalence of anti-HAV antibody in
each group of HIV-positive persons. Nevertheless, after
adjustment for age, sex, route of HIV transmission (injecting
drug use versus sexual transmission), CD4 count, and plasma
HIV RNA load, only older age (AOR 1.284, 95% CI 1.246—
1.322) and IDU (AOR 5.137, 95% CI 3.499—7.542) were inde-
pendently associated with an increased prevalence of anti-
HAV antibody. The AOR for positive anti-HAV antibody in IDU
was 5.497 (95% CI 3.667—8.239) compared with MSM, and
5.157 (95% CI 2.478—10.733) compared with heterosexuals.
On the other hand,MSMwere less likely to have positive anti-
HAV antibody than heterosexuals (AOR 0.507, 95% CI 0.281—
0.913).
In comparison with the other HIV-positive groups and
controls, IDU appeared to have been exposed to HAV much
Figure 1 Prevalence of antibodies against hepatitis A virus according to age-specific groups in controls and HIV-positive persons with
different risk factors for HIV infection (MSM, men having sex with men; IDU, injecting drug users).
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increased rapidly from 2.9% (1/34) in the 21—25 years age
group to 89.4% (93/104) in the 36—40 years age group
(Figure 1). Nearly 90% of the IDU had become seropositive
for HAV after age 36—40 years, compared with heterosexuals
and MSM after age 46—50 years, and controls after age 51—55
years.
In addition to prevalence of anti-HAVantibody, prevalence
of HBsAg, anti-HBc antibody, and anti-HCV antibody also
differed between HIV-positive and HIV-negative persons.
HIV-positive IDU had the highest prevalence of anti-HCV
antibody (98.3%), followed by HIV-positive heterosexuals
(7.4%) and MSM (6.4%), and HIV-negative persons (1.8%)
(Table 1). The overall prevalence of both positive HBsAg
and anti-HBc antibody was significantly higher in HIV-positive
persons of different transmission routes than in HIV-negative
persons. The prevalence of anti-HCV antibody did not differ
between persons with positive and negative anti-HAV anti-
body either in HIV-negative persons or in HIV-positive persons
with different routes of HIV transmission (Table 3).
The prevalence of positive HBsAg was similar among the
three HIV-positive groups: 20.5% in MSM, 18.8% in hetero-
sexuals, and 19.9% in IDU (Table 1), and it was also similar
between persons with positive and negative anti-HAV anti-
body within each HIV-positive group (Table 3). In addition, no
differences in the prevalence of positive anti-HBc antibody
existed among HIV-positive groups: 80.6% in MSM, 80.1% inTable 2 Seroprevalence of hepatitis A virus according to three c
CD4 <200 cells/ml CD4 200—
MSM, n/Na (%) 216/384 (56.2) 50/110 (
Heterosexual 180/222 (81.1) 29/34 (8
IDU 32/38 (84.2) 120/185 (
p-Valueb <0.001 <0.001
MSM, men who have sex with men; IDU, injecting drug users.
a n/N = number of patients with positive anti-hepatitis A virus antibod
results within each CD4 category.
b p-Value, comparisons of hepatitis A seroprevalence among groups o
c p-Value, comparisons of hepatitis A seroprevalence among differenheterosexuals, and 81.6% in IDU (Table 1). However, MSM and
IDU with negative anti-HAV antibody were less likely to have
positive anti-HBc antibody (Table 3). Similarly, HIV-negative
persons with negative anti-HAV antibody had a significantly
lower prevalence of positive HBsAg and anti-HBc antibody
(Table 3). Such differences in the prevalence of HBV markers
between HIV-negative persons with positive and negative
anti-HAV antibody might be explained by the fact that the
higher proportion of persons who were less than 26 years old
grew up in improved sanitary conditions and with universal
childhood HBV vaccination, which started in 1984.26
Discussion
The present study demonstrates that in Taiwan, HIV-positive
IDU were not only at higher risk for HCV infection, but also at
higher risk for HAV infection than HIV-negative persons
(Table 1 and Figure 1). In addition, HIV-positive IDU were
muchmore likely to have positive anti-HAVantibody than HIV-
positive MSM or heterosexuals, especially in younger age
groups (Figure 1). The reported prevalence of anti-HAV anti-
body in IDU in the literature ranges from 32.7% to 85.7%,15—
17,27—31 which is higher compared with that in other popula-
tions, such as MSM, blood donors, or the general popula-
tion.15—17 Because of the different epidemiology of HAV
infection in each study, the reported prevalence of anti-ategories of CD4 count in different HIV-positive groups
350 cells/ml CD4 >350 cells/ml p-Valuec
45.5) 60/147 (40.8) 0.003
5.3) 26/39 (66.7) 0.082
64.9) 177/311 (56.9) 0.003
<0.001
y/number of patients with available anti-hepatitis A virus antibody
f different transmission routes within each CD4 count category.
t CD4 count categories within each transmission group.
Table 3 Comparisons of seroprevalence of hepatitis B and C markers between persons with and without positive anti-hepatitis A
virus antibody in HIV-negative persons and each HIV-positive group
HBsAg-pos p-Value Anti-HBc Ab-pos p-Value Anti-HCV Ab-pos p-Value
MSM, n/Na (%)
Anti-HAV Ab-pos 74/331 (22.4) 0.248 258/307 (84.0) 0.027 24/305 (7.9) 0.144
Anti-HAV Ab-neg 61/326 (18.7) 223/290 (76.9) 14/285 (4.9)
Heterosexual, n/N (%)
Anti-HAV Ab-pos 46/240 (19.2) 0.758 183/226 (81.0) 0.458 19/225 (8.4) 0.324
Anti-HAV Ab-neg 11/63 (17.5) 46/60 (76.7) 2/57 (3.5)
IDU, n/N (%)
Anti-HAV Ab-pos 69/339 (20.4) 0.729 284/326 (87.1) <0.001 321/329 (97.6) 0.169
Anti-HAV Ab-neg 40/209 (19.1) 150/206 (72.8) 208/209 (99.5)
Controls, n/N (%)
Anti-HAV Ab-pos 207/1239 (16.7) <0.001 998/1239 (80.5) <0.001 17/845 (2.0) 0.419
Anti-HAV Ab-pos 133/1342 (9.9) 484/1342 (36.1) 2/219 (0.9)
MSM, men having sex with men; anti-HAVAb, anti-hepatitis A virus antibody; IDU, injecting drug users; HBsAg, hepatitis B surface antigen;
anti-HBc Ab, anti-hepatitis B core antibody; anti-HCV Ab, anti-hepatitis C virus antibody.
a n/N = number of patients with positive test result/number of patients with test result.
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this study, we did not find a higher prevalence of anti-HAV
antibody in MSM compared with that in HIV-positive hetero-
sexuals and IDU. This finding is similar to those of previous
reports,15,19 even though MSM have been reported to have a
higher attack rate and outbreaks of HAV infection.11,12,32
Several studies have been conducted to determine risk
factors for HAV infection in MSM or IDU. The factors asso-
ciated with seropositivity for HAVamong MSM include specific
sex practices (such as oral—anal sex or digital—anal sex),13,14
greater number of sex partners,18 a history of sexually-
transmitted diseases,15 or contact with a person with hepa-
titis A.11 As for IDU, factors associated with seropositivity for
HAV include poor personal hygiene,9 contact with a jaundiced
person,7,9 sharing needles,8,9 being less educated,28 lower
annual incomes,15 older age,17,28 exposure to HBV,28 and jail
incarceration or correctional facility incarceration.27,31 Mod-
ification of behaviors through provision of information and
education, though not impossible, is often difficult among
persons at risk for HAV and HIV transmission. Therefore, the
most efficient method to prevent HAV infection in these high-
risk populations is HAV vaccination.
HIV infection may be associated with a prolongation of
HAV viremia,33 which is considered a possible cause for long-
lasting outbreaks of HAV infection in HIV-positive MSM. Addi-
tionally, HIV might also augment HAV-related liver abnorm-
alities.34 In the present study, approximately 20% of HIV-
positive persons had concurrent HBV infection, and 98% of
HIV-positive IDU were seropositive for anti-HCV antibody.
Increased morbidity and mortality may be anticipated in
these HIV-positive persons, especially IDU, once acute HAV
infection occurs. Although there are concerns about
decreased immunogenicity after vaccination in IDU and
HIV-positive persons,35—38 IDU can mount clinical protective
immune responses after HAV vaccinations despite a relatively
compromised seroconversion rate.10,39
The reported rate of HAV vaccination among MSM has been
as low as 15—21%, even though HAV vaccination is recom-
mended for MSM.40,41 The most common reasons for lack ofHAV vaccination are patients being unaware of vaccination or
not being offered HAV vaccination.41 The HAV vaccination
rate has been reported to be even lower in IDU, at as low as
5—10.3%.28,29 Furthermore, only 49.9% of MSM were offered
HAV vaccination on their first visit to a genitourinary med-
icine clinic, and 75% of persons receiving the first dose of
vaccine did not return for the recommended follow-up sec-
ond dose.42 Therefore, a one-dose policy might be more
practical for those persons with a high default rate. In
immunocompetent persons, the seroconversion rate after
a single dose of HAV vaccination is as high as 95%.43 However,
seroconversion after a single-dose immunization was found
to be only 37—44% in IDU and 44.3% in HIV-infected per-
sons.44,45 Nevertheless, a mass immunization campaign with
a single dose of HAV vaccination for more than 1500 IDU has
successfully controlled an HAV outbreak.10
A universal vaccination policy is less expensive than
screening and vaccinating HAV-susceptible patients when
the prevalence of anti-HAV antibody is less than 35%.42 This
policy becomes more expensive when the prevalence is over
67%. Thus, based on the results of the present study, universal
HAV vaccination without anti-HAV testing should be consid-
ered for IDU who are aged less than 36 years, preferably at or
before age 26—30 years, before the rapid increase of ser-
opositivity for HAVoccurs; for MSM and heterosexuals who are
aged less than 41 years, preferably at or before age 31—35
years. Despite the fact that there is great chance that they
might not return to clinics after the first visit, delaying the
second dose of HAV vaccination for up to 66 months after the
primary vaccination does not seem to influence the immu-
nogenicity of the second dose.46 As for the IDU who are aged
over 36 years and heterosexuals and MSM who are aged over
41 years, anti-HAV testing followed by vaccination for sus-
ceptible patients might be more cost-effective. Of note, HAV
vaccination can be offered inmethadone clinics, correctional
facilities, and jails, which are often the entry points of access
to HIV health services for IDU in Taiwan.
Because it is impossible to predict which young person will
become an IDU or MSM in the future and the seroconversion
e204 H.-Y. Sun et al.rate of HAV vaccination in IDU and HIV-infected persons is
lower than that in healthy adults,43—45 universal childhood
HAV vaccination would be an attractive strategy in the con-
text of the high coverage rate of the universal childhood HBV
vaccination (97—98%) and the existing functioning infrastruc-
ture to deliver the vaccine in Taiwan.47 However, more
studies are needed to assess the cost-effectiveness of uni-
versal HAV vaccination and the generalizability of the results,
since the cost of health care and HAV vaccination in Taiwan
(US$ 30—45 per dose for HAV vaccination) are different from
those of other countries.
There are several limitations in the present study, and
interpretations of the results should be made with caution.
First, not all HIV-positive patients had anti-HAV tests and
there were differences in demographic and clinical charac-
teristics between those tested and those not tested. Second,
the cross-sectional study design precludes us from determin-
ing the incidence of HAV infection in HIV-positive persons,
which might be more important from the viewpoint of public
health. Third, information of study subjects regarding per-
sonal hygiene, living conditions, socioeconomic status, or
illicit drug-taking behaviors were lacking. Thus, factors asso-
ciated with a higher risk of HAV infection in HIV-positive
persons could not be determined. Fourth, HAV vaccination
may affect the prevalence of anti-HAVantibody. In this retro-
spective study, we were not able to collect the data on HAV
vaccination of the study population, although offering HAV
vaccination to the general population is not a common
practice in the clinic setting in Taiwan.
In conclusion, HIV-positive persons have a higher preva-
lence of anti-HAV antibody than HIV-negative controls. The
prevalence differs with different routes of HIV transmission
among HIV-positive persons. HIV-positive IDU who are aged
less than 36 years and MSM and heterosexuals who are aged
less than 41 years, should receive HAV vaccination to avoid
subsequent morbidity andmortality from acute HAV infection
and to reduce the risk for potential HAV outbreaks among
susceptible groups.
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